INNOGEN-B (02591) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results

Bulletin Express

03/10

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March 2026, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and authorise their publication.

The notice was issued under the signature of Chairman Dr. Wang Qinghua. As of the announcement date, the board consists of:

• Executive Directors: Dr. Wang Qinghua, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing • Non-executive Directors: Mr. Ho Kyung Shik and Mr. Heng Lei • Independent Non-executive Directors: Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony

The company has confirmed that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the contents of the announcement.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1103949350"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103949350\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103949350?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103949350","market":"hk","top_or_hot":-1,"title":"INNOGEN-B (02591) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results","media":"Bulletin Express","content":"<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March 2026, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and authorise their publication.</p>\n<p>The notice was issued under the signature of Chairman Dr. Wang Qinghua. As of the announcement date, the board consists of:</p>\n<p>• Executive Directors: Dr. Wang Qinghua, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing  \n• Non-executive Directors: Mr. Ho Kyung Shik and Mr. Heng Lei  \n• Independent Non-executive Directors: Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony</p>\n<p>The company has confirmed that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the contents of the announcement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B (02591) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B (02591) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-10 16:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March 2026, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and authorise their publication.</p>\n<p>The notice was issued under the signature of Chairman Dr. Wang Qinghua. As of the announcement date, the board consists of:</p>\n<p>• Executive Directors: Dr. Wang Qinghua, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing  \n• Non-executive Directors: Mr. Ho Kyung Shik and Mr. Heng Lei  \n• Independent Non-executive Directors: Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony</p>\n<p>The company has confirmed that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the contents of the announcement.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"銀諾醫藥-B","start_time":0,"source_url":"","article_id":"1103949350","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103949350","pubTimestamp":1773132241,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"INNOGEN-B(02591)定于2026年3月23日召开董事会批准2025财年业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March 2026, directors will review and approve the consolidated annual results for the financial year ended 31 December 2025 and authorise their publication.\nThe notice was issued under the signature of Chairman Dr. Wang Qinghua. As of the announcement date, the board consists of:\n• Executive Directors: Dr. Wang Qinghua, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing  \n• Non-executive Directors: Mr. Ho Kyung Shik and Mr. Heng Lei  \n• Independent Non-executive Directors: Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony\nThe company has confirmed that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the contents of the announcement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}